Swiss contract development and manufacturing organization (CDMO) today announced the signing of an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Swiss pharma giant Roche (ROG: SIX) for $1.2 billion.
The Lonza move comes at a time that demand for capacity for commercial biologics is expected to remain high across the CDMO industry as innovative new therapies reach approval.
The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity to meet demand for commercial mammalian contract manufacturing from customers with existing commercial products, and molecules currently on the path to commercialization within the Lonza network. The transaction is expected to close in the second half of 2024, subject to customary closing conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze